NCT06561048Phase 3Recruiting

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Study sponsor: Corvus Pharmaceuticals, Inc. · CRVS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-11Estimated

Enrollment · participants150Estimated

Source updated2026-09-25Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-08 · 1 field changed

Primary completion date changed

− Before

~~Nov 2026~~

+ After

Nov 2027

Check registry source

Study details

Conditions studied

Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Systemic Anaplastic Large Cell Lymphoma; Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell

Treatments or interventions studied

SoquelitinibDrugAlso known as CPI-818
BelinostatDrugAlso known as Beleodaq®
PralatrexateDrugAlso known as Folotyn®

Primary outcomes · main study measures

measure: Progression-free survival; description: Time from first study treatment to first occurrence of progression (as assessed by the Independent Review Committee) or death, whichever occurs first; timeFrame: Up to 4 years post study treatment initiation

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history